<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38520">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01930422</url>
  </required_header>
  <id_info>
    <org_study_id>12 392 02</org_study_id>
    <secondary_id>AOL 2012</secondary_id>
    <nct_id>NCT01930422</nct_id>
  </id_info>
  <brief_title>Effect of Transcranial Direct Current Stimulation (tDCS) on Tobacco Consumption</brief_title>
  <acronym>TABELEC</acronym>
  <official_title>Effect of Transcranial Direct Current Stimulation (tDCS) on Tobacco Consumption.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of the protocol is to evaluate the effect of repeated application for 5
      consecutive days of a real tDCS compared to the application of a placebo tDCS (sham
      procedure) on the evolution of tobacco consumption in the short term between Day 1 and Day
      5.

      The study hypothesis is that a repeated application for 5 consecutive days of a real tDCS on
      the left dorsolateral prefrontal cortex region will reduce the craving induced causing a
      decreased of daily tobacco consumption between Day 1 and Day 5 which can persist at the
      final visit between Day 15 and Day 20.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Smoking is a major public health problem and it is the leading cause of preventable death in
      the world. Care should include education, psychotherapy and treatments, but despite these
      therapeutics, the smoking cessation process is often characterized by relapses. The main
      risk factor for relapse is craving. Neurophysiological studies have provided evidence in the
      understanding of craving. This craving involves surface structures including the
      dorsolateral prefrontal cortex, accessible by neurostimulation. Repetitive neurostimulation
      applies on this structures involved in craving could therefore modulate it. Two non-invasive
      stimulation techniques exist: repetitive transcranial magnetic stimulation (rTMS) and
      transcranial direct current stimulation (tDCS). The choice of tDCS is based on its ease of
      use, excellent tolerance, its better quality of placebo and low cost.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Relative change of individual salivary cotinine.</measure>
    <time_frame>Outcome measure is assessed at Day1 and Day5</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative change of individual salivary cotinine</measure>
    <time_frame>Outcome measure is assessed at  Day5 and between Day15 and Day20.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exhaled carbon monoxide.</measure>
    <time_frame>Outcome measure is assessed at day 0, day 1, day 2, day 3, day 4, day 5 and  between day 15 and day 20.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cigarettes smoked per day</measure>
    <time_frame>Outcome measure is assessed at day 0, day1, day2, day3, day4, day5 and between day 15 and 20</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical feasibility of outpatient</measure>
    <time_frame>Outcome measure is assessed between day 15 and 20.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The feasibility is assessed by the number of smokers following the entire protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of craving</measure>
    <time_frame>Outcome measure is assessed at Day1, day2, day3, day4, day5 and betwenn day 15 to day 20.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement of craving from Day1 to Day5 and at the final visits assessed by a VAS: visual analogue scale from 0 (no urge to smoke at all) to 10 (intense desire compelling smoking) and the questionnaire called the 12-item French Tobacco Craving Questionnaire (FCTQ-12).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Tobacco Use Disorder</condition>
  <arm_group>
    <arm_group_label>Real tDCS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Direct transcranial electrical stimulation (tDCS procedure)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo tDCS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>tDCS procedure</intervention_name>
    <description>The tDCS is a non-invasive neuromodulation method. A stimulator delivers a constant current of low intensity (1-2 mA) applied to the average of two bipolar electrodes placed on the scalp for 20 minutes. This constant current generates a static electric field that selectively modulates the activity of cortical neurones. A tingling sensation under the electrodes appears at the beginning and at the end of stimulation but it is transient and disappears quickly in 30 or 60 seconds.</description>
    <arm_group_label>Real tDCS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham procedure</intervention_name>
    <description>The tDCS placebo differs from the real tDCS by the interruption of stimulation after 30 to 60 seconds and reactivation of this stimulation 30 to 60 seconds before the end of the session, which lasted 20 minutes. The tingling felt at the beginning and the end of the session will be the same as those experienced with real stimulation. The electrodes establishment does not differ with respect to tDCS.</description>
    <arm_group_label>Placebo tDCS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 to 60 years old

          -  Smoking ≥ 5 years

          -  Smoking ≥ 15 manufactured cigarettes per day or ≥ 10 rolled cigarettes per day

          -  Fagerström test ≥ 5

          -  Smokers who have at least an attempt to stop of minimum 7 days

          -  Written informed consent signed by the patient

          -  Affiliated to medical insurance

        Exclusion Criteria:

          -  Co-addiction (cannabis, alcohol, other drugs)

          -  HAD test: D ≥ 8; A + D ≥ 19

          -  Treatment by nicotine replacement therapy, bupropion or varenicline within 30 days
             prior inclusion

          -  Neuropsychiatric disease, considered serious by the investigator

          -  Psychotropic treatment (antidepressant, anxiolytic, antipsychotic)

          -  Skin scalp dermatosis

          -  Pregnancy or breastfeeding. Positive pregnancy test.

          -  Patient under guardianship, trusteeship or judicial protection

          -  Patient in inclusion period for another clinical research protocol
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rose-Marie ROUQUET, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital, Toulouse</name>
      <address>
        <city>Toulouse</city>
        <state>Midi-Pyrénées</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Pich EM, Pagliusi SR, Tessari M, Talabot-Ayer D, Hooft van Huijsduijnen R, Chiamulera C. Common neural substrates for the addictive properties of nicotine and cocaine. Science. 1997 Jan 3;275(5296):83-6.</citation>
    <PMID>8974398</PMID>
  </reference>
  <reference>
    <citation>Wise RA, Bozarth MA. A psychomotor stimulant theory of addiction. Psychol Rev. 1987 Oct;94(4):469-92. Review.</citation>
    <PMID>3317472</PMID>
  </reference>
  <reference>
    <citation>Collins AC, Marks MJ. Progress towards the development of animal models of smoking-related behaviors. J Addict Dis. 1991;10(1-2):109-26.</citation>
    <PMID>2065112</PMID>
  </reference>
  <reference>
    <citation>Pomerleau OF. Individual differences in sensitivity to nicotine: implications for genetic research on nicotine dependence. Behav Genet. 1995 Mar;25(2):161-77. Review.</citation>
    <PMID>7733857</PMID>
  </reference>
  <reference>
    <citation>Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev. 1993 Sep-Dec;18(3):247-91. Review.</citation>
    <PMID>8401595</PMID>
  </reference>
  <reference>
    <citation>Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991 Sep;86(9):1119-27.</citation>
    <PMID>1932883</PMID>
  </reference>
  <reference>
    <citation>Pickens RW, Johanson CE. Craving: consensus of status and agenda for future research. Drug Alcohol Depend. 1992 Jun;30(2):127-31. Review.</citation>
    <PMID>1633752</PMID>
  </reference>
  <reference>
    <citation>Killen JD, Fortmann SP. Craving is associated with smoking relapse: findings from three prospective studies. Exp Clin Psychopharmacol. 1997 May;5(2):137-42.</citation>
    <PMID>9234050</PMID>
  </reference>
  <reference>
    <citation>Shiffman S, Engberg JB, Paty JA, Perz WG, Gnys M, Kassel JD, Hickcox M. A day at a time: predicting smoking lapse from daily urge. J Abnorm Psychol. 1997 Feb;106(1):104-16.</citation>
    <PMID>9103722</PMID>
  </reference>
  <reference>
    <citation>Abrams DB, Monti PM, Pinto RP, Elder JP, Brown RA, Jacobus SI. Psychosocial stress and coping in smokers who relapse or quit. Health Psychol. 1987;6(4):289-303.</citation>
    <PMID>3301320</PMID>
  </reference>
  <reference>
    <citation>Niaura R, Abrams DB, Pedraza M, Monti PM, Rohsenow DJ. Smokers' reactions to interpersonal interaction and presentation of smoking cues. Addict Behav. 1992 Nov-Dec;17(6):557-66.</citation>
    <PMID>1488936</PMID>
  </reference>
  <reference>
    <citation>Shiffman S, Paty JA, Gnys M, Kassel JA, Hickcox M. First lapses to smoking: within-subjects analysis of real-time reports. J Consult Clin Psychol. 1996 Apr;64(2):366-79.</citation>
    <PMID>8871421</PMID>
  </reference>
  <reference>
    <citation>Brody AL, Mandelkern MA, London ED, Childress AR, Lee GS, Bota RG, Ho ML, Saxena S, Baxter LR Jr, Madsen D, Jarvik ME. Brain metabolic changes during cigarette craving. Arch Gen Psychiatry. 2002 Dec;59(12):1162-72.</citation>
    <PMID>12470133</PMID>
  </reference>
  <reference>
    <citation>McClernon FJ, Hiott FB, Huettel SA, Rose JE. Abstinence-induced changes in self-report craving correlate with event-related FMRI responses to smoking cues. Neuropsychopharmacology. 2005 Oct;30(10):1940-7.</citation>
    <PMID>15920499</PMID>
  </reference>
  <reference>
    <citation>Wilson SJ, Sayette MA, Delgado MR, Fiez JA. Instructed smoking expectancy modulates cue-elicited neural activity: a preliminary study. Nicotine Tob Res. 2005 Aug;7(4):637-45.</citation>
    <PMID>16085533</PMID>
  </reference>
  <reference>
    <citation>Smolka MN, Bühler M, Klein S, Zimmermann U, Mann K, Heinz A, Braus DF. Severity of nicotine dependence modulates cue-induced brain activity in regions involved in motor preparation and imagery. Psychopharmacology (Berl). 2006 Mar;184(3-4):577-88. Epub 2005 Aug 13.</citation>
    <PMID>16133128</PMID>
  </reference>
  <reference>
    <citation>Brody AL, Mandelkern MA, Olmstead RE, Jou J, Tiongson E, Allen V, Scheibal D, London ED, Monterosso JR, Tiffany ST, Korb A, Gan JJ, Cohen MS. Neural substrates of resisting craving during cigarette cue exposure. Biol Psychiatry. 2007 Sep 15;62(6):642-51. Epub 2007 Jan 9.</citation>
    <PMID>17217932</PMID>
  </reference>
  <reference>
    <citation>Lee JH, Lim Y, Wiederhold BK, Graham SJ. A functional magnetic resonance imaging (FMRI) study of cue-induced smoking craving in virtual environments. Appl Psychophysiol Biofeedback. 2005 Sep;30(3):195-204.</citation>
    <PMID>16167185</PMID>
  </reference>
  <reference>
    <citation>Due DL, Huettel SA, Hall WG, Rubin DC. Activation in mesolimbic and visuospatial neural circuits elicited by smoking cues: evidence from functional magnetic resonance imaging. Am J Psychiatry. 2002 Jun;159(6):954-60.</citation>
    <PMID>12042183</PMID>
  </reference>
  <reference>
    <citation>Ferguson SG, Shiffman S. The relevance and treatment of cue-induced cravings in tobacco dependence. J Subst Abuse Treat. 2009 Apr;36(3):235-43. doi: 10.1016/j.jsat.2008.06.005. Epub 2008 Aug 20. Review.</citation>
    <PMID>18715743</PMID>
  </reference>
  <reference>
    <citation>Tiffany ST, Cox LS, Elash CA. Effects of transdermal nicotine patches on abstinence-induced and cue-elicited craving in cigarette smokers. J Consult Clin Psychol. 2000 Apr;68(2):233-40.</citation>
    <PMID>10780123</PMID>
  </reference>
  <reference>
    <citation>Singleton EG, Anderson LM, Heishman SJ. Reliability and validity of the Tobacco Craving Questionnaire and validation of a craving-induction procedure using multiple measures of craving and mood. Addiction. 2003 Nov;98(11):1537-46.</citation>
    <PMID>14616180</PMID>
  </reference>
  <reference>
    <citation>Heishman SJ, Singleton EG, Moolchan ET. Tobacco Craving Questionnaire: reliability and validity of a new multifactorial instrument. Nicotine Tob Res. 2003 Oct;5(5):645-54.</citation>
    <PMID>14577981</PMID>
  </reference>
  <reference>
    <citation>Berlin I, Vorspan F, Singleton EG, Warot D, Notides C, Heishman SJ. Reliability and validity of the French version of the tobacco craving questionnaire. Eur Addict Res. 2005;11(2):62-8.</citation>
    <PMID>15785066</PMID>
  </reference>
  <reference>
    <citation>Heishman SJ, Singleton EG, Pickworth WB. Reliability and validity of a Short Form of the Tobacco Craving Questionnaire. Nicotine Tob Res. 2008 Apr;10(4):643-51. doi: 10.1080/14622200801908174.</citation>
    <PMID>18418787</PMID>
  </reference>
  <reference>
    <citation>Berlin I, Singleton EG, Heishman SJ. Validity of the 12-item French version of the Tobacco Craving Questionnaire in treatment-seeking smokers. Nicotine Tob Res. 2010 May;12(5):500-7.</citation>
  </reference>
  <reference>
    <citation>Silagy C, Mant D, Fowler G, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2000;(3):CD000146. Review. Update in: Cochrane Database Syst Rev. 2001;(3):CD000146.</citation>
    <PMID>10908462</PMID>
  </reference>
  <reference>
    <citation>Woolacott NF, Jones L, Forbes CA, Mather LC, Sowden AJ, Song FJ, Raftery JP, Aveyard PN, Hyde CJ, Barton PM. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. Health Technol Assess. 2002;6(16):1-245. Review.</citation>
    <PMID>12269277</PMID>
  </reference>
  <reference>
    <citation>Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2001;(3):CD000146. Review. Update in: Cochrane Database Syst Rev. 2002;(4):CD000146.</citation>
    <PMID>11686953</PMID>
  </reference>
  <reference>
    <citation>Hughes JR, Stead LF, Lancaster T. Anxiolytics and antidepressants for smoking cessation. Cochrane Database Syst Rev. 2000;(2):CD000031. Review. Update in: Cochrane Database Syst Rev. 2000;(4):CD000031.</citation>
    <PMID>10796472</PMID>
  </reference>
  <reference>
    <citation>Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation (Review). Cochrane Database Syst Rev 2011;(2)</citation>
  </reference>
  <reference>
    <citation>Lang N, Hasan A, Sueske E, Paulus W, Nitsche MA. Cortical hypoexcitability in chronic smokers? A transcranial magnetic stimulation study. Neuropsychopharmacology. 2008 Sep;33(10):2517-23. Epub 2007 Dec 5.</citation>
    <PMID>18059439</PMID>
  </reference>
  <reference>
    <citation>Brunelin J, Poulet E, Boeuve C, Zeroug-vial H, d'Amato T, Saoud M. [Efficacy of repetitive transcranial magnetic stimulation (rTMS) in major depression: a review]. Encephale. 2007 Mar-Apr;33(2):126-34. Review. French.</citation>
    <PMID>17675907</PMID>
  </reference>
  <reference>
    <citation>Barr MS, Fitzgerald PB, Farzan F, George TP, Daskalakis ZJ. Transcranial magnetic stimulation to understand the pathophysiology and treatment of substance use disorders. Curr Drug Abuse Rev. 2008 Nov;1(3):328-39. Review.</citation>
    <PMID>19630729</PMID>
  </reference>
  <reference>
    <citation>Johann M, Wiegand R, Kharraz A, Bobbe G, Sommer G, Hajak G, Wodarz N, Eichhammer P. [Repetitiv Transcranial Magnetic Stimulation in Nicotine Dependence]. Psychiatr Prax. 2003 May;30(Suppl 2):129-131. German.</citation>
    <PMID>13130356</PMID>
  </reference>
  <reference>
    <citation>Eichhammer P, Johann M, Kharraz A, Binder H, Pittrow D, Wodarz N, Hajak G. High-frequency repetitive transcranial magnetic stimulation decreases cigarette smoking. J Clin Psychiatry. 2003 Aug;64(8):951-3.</citation>
    <PMID>12927012</PMID>
  </reference>
  <reference>
    <citation>Amiaz R, Levy D, Vainiger D, Grunhaus L, Zangen A. Repeated high-frequency transcranial magnetic stimulation over the dorsolateral prefrontal cortex reduces cigarette craving and consumption. Addiction. 2009 Apr;104(4):653-60. Epub 2009 Jan 12.</citation>
    <PMID>19183128</PMID>
  </reference>
  <reference>
    <citation>Nitsche MA, Paulus W. Excitability changes induced in the human motor cortex by weak transcranial direct current stimulation. J Physiol. 2000 Sep 15;527 Pt 3:633-9.</citation>
    <PMID>10990547</PMID>
  </reference>
  <reference>
    <citation>Gartside IB. Mechanisms of sustained increases of firing rate of neurones in the rat cerebral cortex after polarization: role of protein synthesis. Nature. 1968 Oct 26;220(165):383-4. No abstract available.</citation>
    <PMID>4300961</PMID>
  </reference>
  <reference>
    <citation>Hattori Y, Moriwaki A, Hori Y. Biphasic effects of polarizing current on adenosine-sensitive generation of cyclic AMP in rat cerebral cortex. Neurosci Lett. 1990 Aug 24;116(3):320-4.</citation>
    <PMID>2173816</PMID>
  </reference>
  <reference>
    <citation>Islam N, Aftabuddin M, Moriwaki A, Hattori Y, Hori Y. Increase in the calcium level following anodal polarization in the rat brain. Brain Res. 1995 Jul 3;684(2):206-8.</citation>
    <PMID>7583224</PMID>
  </reference>
  <reference>
    <citation>Gandiga PC, Hummel FC, Cohen LG. Transcranial DC stimulation (tDCS): a tool for double-blind sham-controlled clinical studies in brain stimulation. Clin Neurophysiol. 2006 Apr;117(4):845-50. Epub 2006 Jan 19.</citation>
    <PMID>16427357</PMID>
  </reference>
  <reference>
    <citation>Bikson M, Datta A, Elwassif M. Establishing safety limits for transcranial direct current stimulation. Clin Neurophysiol. 2009 Jun;120(6):1033-4. doi: 10.1016/j.clinph.2009.03.018. Epub 2009 Apr 24.</citation>
    <PMID>19394269</PMID>
  </reference>
  <reference>
    <citation>Poreisz C, Boros K, Antal A, Paulus W. Safety aspects of transcranial direct current stimulation concerning healthy subjects and patients. Brain Res Bull. 2007 May 30;72(4-6):208-14. Epub 2007 Jan 24.</citation>
    <PMID>17452283</PMID>
  </reference>
  <reference>
    <citation>Fregni F, Liguori P, Fecteau S, Nitsche MA, Pascual-Leone A, Boggio PS. Cortical stimulation of the prefrontal cortex with transcranial direct current stimulation reduces cue-provoked smoking craving: a randomized, sham-controlled study. J Clin Psychiatry. 2008 Jan;69(1):32-40.</citation>
    <PMID>18312035</PMID>
  </reference>
  <reference>
    <citation>Boggio PS, Liguori P, Sultani N, Rezende L, Fecteau S, Fregni F. Cumulative priming effects of cortical stimulation on smoking cue-induced craving. Neurosci Lett. 2009 Sep 29;463(1):82-6. Epub 2009 Jul 18.</citation>
    <PMID>19619607</PMID>
  </reference>
  <reference>
    <citation>Boggio PS, Sultani N, Fecteau S, Merabet L, Mecca T, Pascual-Leone A, Basaglia A, Fregni F. Prefrontal cortex modulation using transcranial DC stimulation reduces alcohol craving: a double-blind, sham-controlled study. Drug Alcohol Depend. 2008 Jan 1;92(1-3):55-60. Epub 2007 Jul 19.</citation>
    <PMID>17640830</PMID>
  </reference>
  <reference>
    <citation>Fu M, Fernandez E, Martínez-Sánchez JM, Pascual JA, Schiaffino A, Agudo A, Ariza C, Borràs JM, Samet JM; DCOT Study investigators. Salivary cotinine concentrations in daily smokers in Barcelona, Spain: a cross-sectional study. BMC Public Health. 2009 Sep 3;9:320. doi: 10.1186/1471-2458-9-320.</citation>
    <PMID>19728886</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 21, 2014</lastchanged_date>
  <firstreceived_date>June 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Direct transcranial electrical stimulation (tDCS)</keyword>
  <keyword>Sham procedure</keyword>
  <keyword>Tobacco consumption</keyword>
  <keyword>Craving</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
